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Abstract
Non-steroidal anti-inflammatory drugs are commonly used in implant dentistry for management of post-operative
pain. The objective of this systematic review was to analyse the effect of non-steroidal anti-inflammatory drugs on
the osteogenic activity of osteoblasts with an emphasis on its effect on osseointegration. A systematic literature
search for in vitro, animal models, and clinical trials was conducted using Ovid, PubMed, Scopus, and Web of
Science databases. Articles published since the introduction of selective COX-2 inhibitors, between January 1999
and July 2018, were selected. The integrated search followed the PRISMA statement with the following key terms:
non-steroidal anti-inflammatory drug/s, titanium, osseointegration, and osteoblast. The review is registered at
PROSPERO database: CRD42016051448. The titles and abstracts of each research article in the initial search (n = 875)
were independently screened by two reviewers. A third independent reviewer reviewed the articles that were
included by one but excluded by the other reviewer. This resulted in the cataloguing of 79 full-text manuscripts
where the articles were assessed for the following criteria: the study investigates the effects of NSAIDs on
osteoblasts, explores the COX pathway and its effect on osteogenic activity, and compares the effects of NSAIDs on
osteoblasts with a control group. A total of 13 articles have been included for qualitative synthesis. There is a lack
of consensus in the literature to explicitly conclude that there is a relationship between the use of post-operative
NSAIDs and failed osseointegration; however, osseointegration does not appear to be negatively affected by
NSAIDs in the human clinical studies.
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Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are a
group of drugs with anti-inflammatory, analgesic, and anti-
pyretic effects. They are commonly used in dentistry for
management of dental pain associated with inflammation.
NSAIDs exert their effects through the inhibition of the
cyclooxygenase (COX) enzyme, therefore interfering with
the synthesis of prostaglandins (PG) and thromboxanes;
PGs and thromboxanes are inflammatory mediators that
are responsible for pain. COX has three isoforms: COX-1,
COX-2, and COX-3. COX-1 exhibits characteristics of a
constitutive enzyme, as its activity is associated with the
involvement of PGs and thromboxanes in controlling
normal physiological functions [1]. COX-2 exhibits charac-
teristics of an inducible enzyme in inflammatory cells and
is activated in response to pathological stimuli [2]. COX-3
is a variant of COX-1, though it shares the characteristics
of both COX-1 and COX-2. The osseointegration process
that is observed after implant insertion can be compared to
bone fracture healing through the process of an inflamma-
tory response in which the recruitment of osteoprogenitor
cells occurs, followed by their downstream differentiation
into osteoblasts that leads to bone deposition on the
implant surface [3, 4]. COX-1 is expressed in normal bone
and at the site of bone fracture, whilst COX-2 is
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upregulated during inflammation and the initial stages of
bone repair [5]. The effects of NSAIDs on altering bone
growth, remodelling, and repair are generally not consid-
ered when prescribed for post-operative pain management
after implant placement.
Hypoxia occurs locally in bone tissues when pathological
conditions such as implant placement and bone fractures
arise [6, 7]. It has been established, through clinical studies
of bone cultures, that hypoxia is directly responsible for
directing the synthesis of prostaglandin E (PGE) by osteo-
blasts [6]. Therefore, the presence of the COX enzymes in
bone healing is of importance [6]. Prostaglandins have the
capacity to influence bone metabolism and can both induce
and inhibit tissue repair mechanisms [6]. Local administra-
tion of PGE1 has been shown to stimulate bone formation,
increase alveolar bone height, and induce formation of new
cementum and periodontal ligament adjacent to the site of
delivery in canine mandibles [8, 9]. Furthermore, PGE2 has
been shown to stimulate replication and differentiation of
osteoblasts cultured on smooth titanium surfaces thereby
increasing bone formation around titanium implants [10].
Additionally, PGs can also inhibit the formation and
growth of osteoblasts [6]. Therefore, altered PG levels as a
result of COX inhibition can have a negative impact on the
role of PG in bone tissue, potentially causing a shift in pre-
cursor cell action towards bone resorption [6].
Cyclooxygenases have an important role in the
production of PGs where these enzymes in bone tissues
show increased activity under the influence of
hypoxia-inducible factors [6, 11]. Therefore, local activity
of COX enzymes promotes bone formation and resorp-
tion through the production of PGs [12]. Non-selective
NSAIDs are reported to inhibit the activity of COX-1
equally, if not more than COX-2 [2]. Therefore, NSAIDs
inhibit the production of PGs at the site of implant
placement or fracture, thereby influencing the bone
healing cascade [13]. There is evidence from animal
studies that indicate that COX-2 inhibitors delay done
healing in diaphyseal fracture models in rats [13]. How-
ever, the exact roles of COX-1 and COX-2 in the PG
production has not been ascertained in humans, and
assumptions have been made suggesting a milder or
non-significant inhibitory effect of selective COX-2
inhibitors on bone healing when compared to a
non-selective COX inhibitor [2, 13]. Furthermore, a
systematic review conducted by Marquez-Lara et al.
highlighted the great variability regarding the impact of
NSAIDs on bone healing, and that there is no consensus
regarding the impact of NSAIDs following orthopaedic
procedures [14]. Therefore, the rationale of the present
systematic review is to address the gaps in the literature
by identifying if variables such as the dosage, duration of
administration, and selectivity of post-operative NSAIDs
negatively affect osseointegration.
Material and methods
Protocol and registration
The systematic review was conducted in accordance with
the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement [15]. The review is
registered at PROSPERO database, and the review protocol
can be accessed at http://www.crd.york.ac.uk/PROSPERO/
display_record.php?ID=CRD42016051448.
The PROSPERO registration number is CRD4201605
1448.
Eligibility criteria
The review included in vitro, clinical and in vivo studies;
animal models. Articles published since the introduction
of selective COX-2 inhibitors in 1999 were included [3].
Studies published outside this time period, not in the Eng-
lish language, non-peer reviewed, and review studies were
excluded.
Information sources
An electronic search into four databases: Ovid, Pubmed,
Scopus, and Web of Science was performed to sys-
tematically identify the available literature. Articles
published between January 1, 1999, and July 7, 2018,
were considered.
Focus question
The focus question, used to guide the search strategy,
according to the PICO schema is “Will variables such as
the dosage, duration of administration, and selectivity of
post-operative NSAIDs impair the bone healing around
titanium implants?”
Search strategy
The search string comprised the combination of medical
subject headings (MeSH) and free keywords. The linkage
was conducted using the Boolean operator (AND, OR).
The choice of keywords was intended to be broad to
maximise the number of relevant studies considered.
The following search strategy was applied to Ovid and
PubMed:
1) (anti inflammatory agents, non steroidal[MeSH
Terms]) AND osseointegration[MeSH Terms]
2) (anti inflammatory agents, non steroidal[MeSH
Terms]) AND osteoblast[MeSH Terms]
3) (anti inflammatory agents, non steroidal[MeSH
Terms]) AND dental implants[MeSH Terms]
Furthermore, the following search strategy was applied
to Scopus and Web of Sciences to supplement records
identified through Ovid and PubMed:
(non steroidal anti inflammatory agent OR non ster-
oidal anti inflammatory agents OR non steroidal anti
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inflammatory drug OR non steroidal anti inflammatory
drugs OR cyclooxygenase inhibition OR COX inhibition
OR ibuprofen OR celecoxib) AND (osseointegration OR
osteoblast OR osteoblasts OR titanium implant OR ti-
tanium implants OR dental implant OR dental implants)
Study selection
The titles and abstracts of each research article in the ini-
tial search were independently screened by the primary
(JDL) and the second reviewer (TJ). A third independent
reviewer (MN) reviewed the articles that were included by
one but excluded by the other reviewer. The full-text
manuscripts of the articles were catalogued in accordance
to the “Eligibility criteria” section as mentioned above and
were assessed for the following criteria:
 The study explored the COX pathway and its role in
osseointegration.
 The effects of NSAIDs on osteoblasts attached to
titanium are investigated (in vitro studies).
Data collection process
The full-text manuscripts of included studies were catalo-
gued into in vitro, clinical, and in vivo studies. The data
from the included studies were independently extracted by
the primary (JDL) and the second reviewer (TJ) according
to the “Data items” section as listed below. Disagreements
or uncertainties were discussed with the third reviewer
(MN) until an agreement was reached.
Data items
The data collected from the included studies were ar-
ranged in the following fields:
 Author (year)—reveals the author/s and year of
publication
 Sample (size)—describes the sample and sample size
used in the study
 Treatment group (size)—describes the treatments
used in study
 Methodology—describes the method of drug
delivery
 Parameter—describes the parameter/s that are
measured
 Outcome—describes the outcome/s of the
experiments
Quality and risk of bias in individual studies
The quality and risk of bias assessments were performed
independently by two reviewers (JDL and TJ) during the
data extraction process. Any disagreements or uncertain-
ties were discussed with the third reviewer (MN) until an
agreement was reached. The quality and bias assessment
for all studies addressed various bias domains. A Modified
CONSORT checklist of items for reporting in vitro studies
of dental materials outlined by Faggion (Tables 1 and 2)
was used to assess quality and risk of bias of included in
vitro studies [16]. The Cochrane Collaboration’s Tool
(Table 3) was used to assess quality and risk of bias of
included human clinical studies [17]. A quality assessment
of the methodology of the animal studies (Table 4) has
been performed according to items (Table 5) of the
ARRIVE guidelines [18].
Synthesis of results
The relevant data collected for qualitative synthesis are
summarised in three critical analysis tables: in vitro
studies (Table 6), clinical studies (Table 7), and in vivo
studies (Table 8).
Statistical analysis
No meta-analyses could be performed due to the hetero-
geneity between the studies—different samples, experi-
mental groups (drugs and concentrations), study models,
and outcome measures.
Results
Study selection
The electronic search in the databases of Web of Science,
PubMed, Ovid, and Scopus resulted in the identification
of 875 potential titles and abstracts. After removal of the
duplicates, independent screening of the abstracts resulted
in the selection of 79 studies for assessment of eligibility.
A total of 13 studies were eligible and are included in the
systematic review (Fig. 1).
Exclusion of studies
The eligibility and study selection criteria as mentioned
above were applied to the 79 full-text articles. A total of
66 studies were excluded after a full-text assessment for
the following reasons:
 The study did not explore the role of COX pathway
in osseointegration (n = 26).
 The effects of NSAIDs on osteoblasts were not
investigated on titanium (n = 24).
 The study was a systematic review (n = 16).
Study characteristics
The included studies were catalogued into three groups
characterised by the type of study: in vitro studies
(Table 6), clinical studies (Table 7), and in vivo studies
(Table 8). The cataloguing provided a clearer under-
standing of the effects of NSAIDs in osseointegration in
various study models, ultimately contributing to the sen-
sitivity of the systematic review.
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Quality and risk of bias assessment
The quality and risk of bias assessments of included
studies are summarised in Tables 1, 2, 3, 4, and 5. The
quality assessment revealed a high risk of bias (for one
or more domain) for most of the included studies. The
included in vitro studies had high risk of bias according
to the Modified CONSORT checklist [16, 19, 20]. One
clinical study was classified as unclear risk of bias (for
one or more domain) according to the Cochrane Collab-
oration’s Tool [17, 21]. An in vivo animal study had an
unclear risk of bias according to the ARRIVE guidelines
[18, 22].
Discussion
Non-steroidal anti-inflammatory drugs are widely used in
clinical dentistry to manage post-operative inflammation
and pain. Two systematic reviews have been performed to
review the literature concerning the possible influence of
NSAIDs on the osseointegration of titanium implants: a
review conducted by Gomes et al. concluded that osseoin-
tegration is impaired in the presence of conventional
NSAIDs, whilst the review conducted by Kalyvas et al.
concluded that short-term post-operative NSAIDs do not
appear to negatively impact osseointegration [3, 4]. Des-
pite these conflicting conclusions regarding post-operative
use of NSAIDs, both Gomes et al. and Kalyvas et al.
agreed that prolonged or long-term use of NSAIDs, par-
ticularly in patients with chronic diseases, impaired
osseointegration and, therefore, reduced the success of
implant surgery [3, 4]. The current review extends on
these existing reviews by identifying if dosage, duration of
administration, and selectivity of post-operative NSAIDs
impair osseointegration.
In vitro studies
The effects of NSAIDs on the osteogenic activity of oste-
oblasts have been extensively studied at the molecular
pharmacological level [23]. However, only two studies
have been identified that investigated the effect of
NSAIDs on osteoblasts attached to titanium surfaces
(Table 6). In the study conducted by Boyan et al., their
results demonstrated that a non-selective COX inhibitor
(indomethacin, 0.1 μM), a selective COX-1 inhibitor
(resveratrol, 1 and 10 μM), and a selective COX-2 in-
hibitor (NS-398, 1 and 10 μM) did not have a significant
effect on the number of cells derived from human osteo-
sarcomas [20]. Furthermore, Boyan et al. demonstrated
that the NSAIDs reduced prostaglandin E2 (PGE2) pro-
duction of cells attached to a rough titanium surface.
Their results indicated that both COX-1 and COX-2 are
involved in the production of osteocalcin, PGE2, and
TGF-β1 by osteoblasts [20]. They also demonstrated that
osteoblasts produced increased levels of PGE2 on rough
titanium surfaces and that this was correlated with in-
creased alkaline phosphatase activity and osteocalcin
production [20]. This suggests that PGE2 may have a
role in osteoblast proliferation and differentiation on ti-
tanium surfaces, and that this favourable effect of PGE2
Table 1 Quality assessment of in vitro studies according to the items of the Modified CONSORT checklist [16]
Study 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Summary assessment
Arpornmaeklong et al. [19] + ? + + – – – – n/a + + – + – High
Boyan et al. [20] + + + + – – – – n/a + + – + – High
Key: (+) = low risk of bias, (?) = unclear risk of bias, (−) = high risk of bias
Table 2 Modified CONSORT checklist of items for reporting in
vitro studies of dental materials [16]
Item Domain
1 Abstract: structured summary of trial design, methods, results,
and conclusions
Introduction
2 Scientific background and explanation of rationale with specific
objectives and/or hypotheses
Methods
3 Intervention: the intervention for each group, including how
and when it was administered, with sufficient detail to enable
replication
4 Outcomes: completely defined, pre-specified primary and
secondary measures of outcome, including how and when
they were assessed
5 Sample size: how sample size was determined
6 Randomisation: method used to generate the random allocation
sequence
7 Allocation: mechanism used to implement the random allocation
sequence, describing any steps taken to conceal the sequence
until intervention was assigned
8 Implementation: who generated the random allocation sequence,
who enrolled teeth, and who assigned teeth to intervention
9 Blinding: if done, who was blinded after assignment to
intervention and how
10 Statistics: statistical methods used to compare groups for primary
and secondary outcomes
Results
11 For each primary and secondary outcome, results for each group,
and the estimated size of the effect and its precision
Discussion
12 Trial limitations, addressing sources of potential bias, imprecision,
and, if relevant, multiplicity of analyses
Other information
13 Sources of funding and other support role of funders
14 Where the full trial protocol can be accessed, if available
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was inhibited when a NSAID was present [20]. Arpom-
maeklong et al. found that a non-selective COXinhibitor
(indomethacin, 0.1 μM) and a selective COX-2 inhibitor
(celecoxib, 1.5, 3.0, and 9.0 μM) inhibited the growth of
cell cultures derived from rat calvarias, where the effect
was dose-dependent in the cultures treated with cele-
coxib [19]. Furthermore, Arpommaeklong et al. demon-
strated that PGE2 levels were significantly lower in the
groups that were treated with a NSAID, and have postu-
lated that PGE2, consistent with Boyan et al., may have a
role in osteoblast growth and differentiation [19, 20].
Clinical studies
The clinical evidence demonstrating the effects of
NSAIDs on the osseointegration of titanium dental im-
plants is limited with only two clinical trials and one
retrospective study identified in the database searches
(Table 7). In the clinical trial conducted by Alissa et al.,
the effect of a 7-day post-operative course of ibuprofen
(600 mg, taken four times daily) on the marginal bone
level around dental implants was investigated [21]. They
found that there were no statistically significant differ-
ences between the treated and placebo groups in the
mean marginal bone level around dental implants at 3
and 6 months after implant placement [21]. In a similar
clinical trial conducted by Sakka et al., the effect of a
7-day course of ibuprofen (600 mg, taken four times
daily) on the marginal bone level around dental implants
was also investigated [24]. They found that there were
no significant differences between the ibuprofen and
non-ibuprofen groups, consistent with the findings of
Alissa et al., when comparing the changes in marginal
bone level around dental implants [24]. However, a
retrospective study conducted by Winnett et al. postu-
lated that the adverse biological events following dental
implant placement were associated with perioperative
use of NSAIDs [25]. Winnett et al. reported a total loss
of 197 dental implants due to failed osseointegration
from patients with failing implant/s (468 implants in 104
patients) treated in a postgraduate dental clinic (between
1979 and 2012). The patients (n = 60) that used NSAIDs
peri-operatively experienced a total of 119 failed
implants, whilst the non-NSAID cohort (n = 44) experi-
enced a total of 78 failed implants. Winnett et al. identi-
fied that ibuprofen (600 mg, taken four times daily) was
the most commonly prescribed; however, other
prescribed NSAIDs included Ketorolac, Vioxx, Celebrex,
Diflunisal, Meloxicam, and Naproxen [25]. Despite the
clinical trials conducted by Alissa et al. and Sakka et al.,
both of whom have demonstrated that a 7-day
post-operative course of ibuprofen (600 mg, taken four
times daily) did not significantly affect bone levels around
dental implants at 3 and 6 months after placement, the
data gathered by Winnett et al. indicates that NSAIDs
may have detrimental effect on osseointegration [25].
Animal studies
The influence of NSAIDS on bone healing in animal
models has been shown to be related to the duration of
treatment and drug selectivity [5]. A total of seven stud-
ies were identified that investigated the effect of NSAIDs
on the osseointegration of titanium implants in animals:
mice, rabbits, and rats (Table 8).
The duration of treatment is a factor to consider when
using NSAIDs, and a study conducted by Goodman et
al. investigated the effect of a selective COX-2 inhibitor
Table 3 Quality and bias assessment of human clinical studies using The Cochrane Collaboration’s Tool [17]
Study Random sequence
generation
Allocation
concealment
Blinding of
participants/personnel
Blinding of
outcome assessment
Incomplete
outcome data
Selective
reporting
Summary
assessment
Alissa et al. [21] + + + ? + + Unclear
Sakka et al. [24] – – – + + + High
Winnett et al. [25] n/a – – – ? + High
Key: (+) = low risk of bias, (?) = unclear risk of bias, (−) = high risk of bias, n/a= not available
Table 4 Quality assessment of the methodology of the animal studies according to the items of the ARRIVE guidelines [18]
Study 5 6 7 8 9 10 11 12 13 Summary assessment
Cai et al. [22] + ? + + ? ? ? + + Unclear
Chikazu et al. [30] + – + + – – ? + + High
Goodman et al. [29] ? + + + – ? – + + High
Goodman et al. [26] ? + + + – ? – + + High
Pablos et al. [31] + ? + + – – ? + + High
Ribeiro et al. [27] + ? + + – – ? + + High
Ribeiro et al. [28] + ? + + – – ? + + High
Salduz et al. [32] – + + + ? – + + + High
Key: (+) = low risk of bias, (?) = unclear risk of bias, (−) = high risk of bias
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(rofecoxib, 12.5 mg/kg/day) administered for 6 weeks on
bone growth in a bone harvest chamber during three
different time periods: initial 2 of the 6 weeks, final 2 of
the 6 weeks, and continuously for 6 weeks [26]. The
bone harvest chamber was a titanium device that was
implanted into the tibia of rabbits and had an inner re-
movable core with canals that allowed for bone ingrowth
into the inner chamber. Their results revealed that rofe-
coxib given continuously for 6 weeks significantly re-
duced bone ingrowth and osteoblasts per area compared
with the control (no treatment), whilst rofecoxib given
for 2 weeks did not appear to interfere with bone in-
growth and number of osteoblasts [26]. Furthermore,
the studies conducted by Ribeiro et al. investigated the
effect of long-term administration (60 days) of a select-
ive COX-2 inhibitor (meloxicam, 3 mg/kg/day) on the
bone growth on a titanium implant [27, 28]. Their re-
sults also indicated that long-term use of a selective
COX-2 NSAID significantly reduces bone-to-implant
contact, bone area, and bone density, ultimately leading to
failed osseointegration [27]. The data gathered in both
studies suggest that duration of treatment is an important
factor in the use of selective COX-2 NSAIDs, as short pe-
riods of rofecoxib and meloxicam did not adversely affect
osseointegration [26, 27].
The COX selectivity of NSAIDs and their interference
with prostaglandin synthesis have been shown to inhibit
bone healing [23]. Goodman et al. performed a
follow-up study where the titanium bone harvest cham-
ber was again implanted into the tibia of rabbits and the
rabbits were treated with water (control), a non-selective
COX inhibitor (naproxen, 110 mg/kg/day), or a selective
COX-2 inhibitor (rofecoxib, 12.5 mg/kg/day) for a
4-week period [29]. Their results again demonstrated
that COX-2 inhibition significantly decreased bone in-
growth, where rofecoxib also decreased the number of
osteoblasts per area [29]. Furthermore, the conclusions
by Goodman et al. were supported by the study by Chi-
kazu et al. where titanium implants were inserted in
wild-type and COX-2-knockout mice [30]. Their results
revealed that the expression of COX-2 was induced in
bone surrounding the implants in wild-type mice, but
not in COX-2-knockout mice and that the bone-to-implant
Table 5 Items of the ARRIVE Guidelines [18]
Item Domain
5 Ethical statement
6 Study design
7 Experimental procedures
8 Experimental animals
9 Housing and husbandry
10 Sample size
11 Allocating animals to experimental
groups
12 Experimental outcomes
13 Statistical analysis
Table 6 In vitro studies that investigated the effect of NSAIDs on osteoblasts attached to titanium surfaces
Study (year) Sample Treatment group Methodology Parameter Outcome
Arpornmaeklong
et al. (2009) [19]
Mouse calvaria
cell line (MC3T3-E1)
Indomethacin
0.1 μM
Celecoxib 1.5 μM
Celecoxib 3.0 μM
Celecoxib 9.0 μM
Control
Incubation in treatment
medium for 5 days.
Investigations were
performed in three
experimental phases:
static, log, and plateau
The following parameters
were assessed at 1, 3, and
5 days: cell attachment, cell
growth, cell differentiation,
secretion of PGE2
Cells were able to grow and
attach to titanium surface for
all treatment groups.
Indomethacin and celecoxib
cell growth on days 3 and 5
in static phase and on day 3
in log phase.
Indomethacin and celecoxib
caused a significant decrease
PGE2 concentration in static
and plateau but not log
phases.
Boyan et al.
(2001) [20]
Human osteosarcoma
cell line (MG63)
Indomethacin
0.1 μM
Resveratrol
1 μM
Resveratrol
10 μM
NS-398 1 μM
NS-398 10 μM
Incubation in treatment
medium for 5 days.
Cells were cultured on
tissue culture plastic,
smooth titanium, and
two rough titanium
surfaces: grit-blasted/acid-
etched and titanium-
plasma sprayed
The following parameters
were assessed after 5 days:
osteocalcin content, PGE2
content, and TGF-β1 content.
Indomethacin, resveratrol,
and NS-398 had no effect
on osteocalcin content.
Indomethacin and
resveratrol blocked PGE2
production. NS-398 had no
effect on PGE2 production
on smooth surfaces but
caused a reduction on
rough surfaces.
Indomethacin blocked TGF-β1
production on rough
surfaces. Resveratrol blocked
TGF-β1 on TPS. NS-398 did
not cause TGF-β1 inhibition.
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contact was minimal in newly formed bone in
COX-2-knockout mice [30]. The data collected by Good-
man et al. and Chikazu et al. postulated that COX-2 may
have an important role in osseointegration [26, 30]. How-
ever, a study conducted by Pablos et al., that investigated
the effect of a non-selective COX inhibitor (diclofenac,
1.07 mg/kg/day) and a selective COX-2 inhibitor (meloxi-
cam, 0.2 mg/kg/day) administered for 5 days on
peri-implant healing in rats, revealed that diclofenac
delayed peri-implant bone healing and negatively affected
the bone-to-implant contact, whereas meloxicam had no
negative effect on peri-implant healing [31]. The results of
Pablos et al. were inconsistent with the results of the study
conducted by Cai et al. that also investigated the effect of
diclofenac (2 mg/kg/day) and a selective COX-2 inhibitor
(parecoxib, 1.5 mg/kg/day) administered for 7 days on the
osseointegration of titanium implants in rabbit calvarias.
Their results revealed no statistically significant differences
between the experimental groups and the control [22].
Furthermore, a recent study conducted by Salduz et al. that
investigated the effect of a non-selective COX inhibitor
(diclofenac, 5 mg/kg/day) and a selective COX-2 inhibitor
(celecoxib, 3 mg/kg/day) administered for 8 weeks on bone
growth and osseointegration on two different alternative
titanium surfaces revealed no statistically significant differ-
ences in the biomechanical and histological results between
the experimental groups and the control, suggesting that
long-term use of NSAIDs does not affect osseointegration
[32]. The data collected in animal studies regarding
duration of treatment and drug selectivity is inconsistent,
and there is a lack of consensus on the influence of
NSAIDs on osseointegration in animal models.
Limitations
The majority of the included studies revealed a high risk of
bias, and conclusions from studies that have a high risk of
bias are sufficient to affect interpretation of data [16–18].
Publication and selection bias is apparent in several
included studies, as the negative effects of NSAIDs on
osseointegration can be expected in the studies that
administered NSAID at a high concentration and/or for a
prolonged period of time. The conclusions of this system-
atic review were largely based on animal studies, as there
are very few published in vitro and clinical studies relating
to the effect of NSAIDs on osseointegration. The effects of
NSAIDs on osseointegration in animals cannot be
Fig. 1 PRISMA flow diagram of literature search
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translated to humans due to the vastly different
pharmacokinetics.
Conclusions
The analgesic and therapeutic effects of NSAIDs are
achieved by COX-2 inhibition [4]. It is likely that COX
inhibition by NSAIDs is detrimental to the bone healing
process, given the favourable actions of PG on this process
[4]. Osteoblasts have the capacity to produce PGs, where
PGE2 is most abundant, through the COX pathway though
the evidence asserting that PGs have a direct role in bone
healing is inconclusive [1, 23]. Furthermore, there is insuffi-
cient evidence in the current literature to explicitly
conclude that there is a relationship between the use of
NSAIDs and early implant failure. However, osseointegra-
tion does not appear to be negatively affected by NSAIDs
in the human clinical studies, which contrasts with the
experimental in vitro and in vivo animal studies. Further-
more, there are no human clinical studies that have investi-
gated the effect of a selective COX-2 NSAID on
osseointegration. Therefore, further research with an em-
phasis in human clinical studies comparing the effect of the
COX selectivity of NSAIDs on osseointegration is required.
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